You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 多重利好疊加 基石藥業(2616.HK)大漲9%
格隆匯 06-09 11:28
格隆匯6月9日丨基石藥業(2616.HK)大幅拉昇至8.9%,報13.94港元有望衝擊階段新高,暫成交3530萬港元,總市值1達65億港元。基石藥業日前獲新加坡政府投資有限公司增持89.25萬股,涉資約1170.69萬港元。此前公司宣佈期中分析顯示舒格利單抗在對1I期非小細胞肺癌適應症患者的註冊性試驗中達到了主要研究終點,公司預計2021年將收穫累累碩果( 45項新藥獲批、提交5項以上新藥上市申請、深化與輝瑞的合作等)。招商證券(香港)認為公司與同業相比仍被低估,並有多項短期催化劑。予目標價19.1港元,維持買入評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account